Merck's business development chief Sunil Patel says the drugmaker wants more deals as it diversifies beyond Keytruda ahead of its 2028 patent cliff.
Pfizer gives Medicus Pharma co-development rights to ADC PF-08046031 for $12M upfront; Novartis consolidating Basel biologics ...
Cityblock raised $116M Series E and acquired Homeward Health to expand Medicare Advantage services, as digital health sees ...
Akeso, Summit say ivonescimab hit the OS bar in China's Phase 3 HARMONi-2 trial vs. Keytruda; full data due at a future ...
GSK to spend $110M upfront licensing Hutchmed's KRAS-EGFR cancer drug HMPL-A830, up to $1.295B total, pending antitrust ...
Three patient deaths in Novartis' autoimmune CAR-T trials raise questions about risks of the therapy in non-fatal diseases.
FDA's Asha Das overruled agency reviewers to grant Replimune's melanoma drug Tudriqev accelerated approval, newly released memos show.
UK regulator halts Tavneos sales; uniQure seeks Huntington's gene therapy approval. Plus Regeneron, Novocure, Jazz, Ascendis, ...
Two pediatric deaths in Chinese CRISPR trials reignite debate over AAV delivery risks, as many of the 15 genetic-medicine experts Endpoints spoke with point to high viral doses rather than gene ...
Google's Gemini now lets users book appointments via Zocdoc. Google Health Chief Michael Howell and Zocdoc CEO Oliver Kharraz ...
Trump strikes MFN drug-pricing deals with 9 more drugmakers as Incyte joins quietly; Oz says 600K seniors signed up for CMS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results